Secondary Endpoints: Response Rate, Progression-Free Survival, Overall Survival
PD
DISEASE, BEST
Of the 21 patients treated at the MTD, 19 patients met criteria for response assessment per protocol. Two patients were not evaluable because they withdrew from therapy or discontinued treatment due to physician decision. Best responses by RECIST criteria were: 6 (29%) partial responses; 12 patients (57%) with stable disease, and 1 (5%) patient with progression prior to completion of 1 cycle of therapy (Best response by RECIST 1.1. *The one patient noted as a PD had a target lesion that met criteria for stable disease, but a non-target lesion fulfilled criteria for PD, so the overall response was PD.
